Suchergebnisse - Robert Z. Orlowski

Treffer weiter einschränken
  1. 1
    The role of the ubiquitin-proteasome pathway in apoptosis

    The role of the ubiquitin-proteasome pathway in apoptosis von Robert Z. Orlowski

    Veröffentlicht 1999
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  2. 2
    NF-κB as a therapeutic target in cancer

    NF-κB as a therapeutic target in cancer von Robert Z. Orlowski, Albert S. Baldwin

    Veröffentlicht 2002
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  3. 3
    The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer

    The role of the ubiquitination-proteasome pathway in breast cancer: Applying drugs that affect the ubiquitin-proteasome pathway to the therapy of breast cancer von Robert Z. Orlowski, Elizabeth Claire Dees

    Veröffentlicht 2002
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  4. 4
    The Immunoproteasome as a Target in Hematologic Malignancies

    The Immunoproteasome as a Target in Hematologic Malignancies von Deborah J. Kuhn, Robert Z. Orlowski

    Veröffentlicht 2012
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  5. 5
    Proteasome inhibitors in the treatment of multiple myeloma

    Proteasome inhibitors in the treatment of multiple myeloma von Jatin J. Shah, Robert Z. Orlowski

    Veröffentlicht 2009
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  6. 6
    Proteasome inhibitors in cancer therapy

    Proteasome inhibitors in cancer therapy von Elisabet E. Manasanch, Robert Z. Orlowski

    Veröffentlicht 2017
    Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  7. 7
    Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis

    Evidence That Inhibition of p44/42 Mitogen-activated Protein Kinase Signaling Is a Factor in Proteasome Inhibitor-mediated Apoptosis von Robert Z. Orlowski, George W. Small, Yue Shi

    Veröffentlicht 2002
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  8. 8
    Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma

    Pheochromocytoma/Paraganglioma: Review of Perioperative Management of Blood Pressure and Update on Genetic Mutations Associated With Pheochromocytoma von Lauren Fishbein, Robert Z. Orlowski, Debbie L. Cohen

    Veröffentlicht 2013
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  9. 9
    Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma

    Biological Effects of the Pim Kinase Inhibitor, SGI-1776, in Multiple Myeloma von Fabiola Cervantes-Gomez, Lisa S. Chen, Robert Z. Orlowski, Varsha Gandhi

    Veröffentlicht 2013
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  10. 10
    Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance

    Mitogen-Activated Protein Kinase Phosphatase-1 Is a Mediator of Breast Cancer Chemoresistance von George W. Small, Yue Shi, Linda S. Higgins, Robert Z. Orlowski

    Veröffentlicht 2007
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  11. 11
    Osteoblastic niche supports the growth of quiescent multiple myeloma cells

    Osteoblastic niche supports the growth of quiescent multiple myeloma cells von Zheng Chen, Robert Z. Orlowski, Michael Wang, Larry W. Kwak, Nami McCarty

    Veröffentlicht 2014
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  12. 12
    Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA

    Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITA von Richard J. Jones, Chad C. Bjorklund, Veerabhadran Baladandayuthapani, Deborah J. Kuhn, Robert Z. Orlowski

    Veröffentlicht 2012
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  13. 13
    Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

    Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhib... von Deborah J. Kuhn, Sally A. Hunsucker, Qing Chen, Peter M. Voorhees, Marian Orłowski, Robert Z. Orlowski

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  14. 14
    Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors

    Expression of histone deacetylases in lymphoma: implication for the development of selective inhibitors von Annunziata Gloghini, Daniela Buglio, Noor M. Khaskhely, Georgios Georgakis, Robert Z. Orlowski, Sattva S. Neelapu, Antonino Carbone, Anas Younes

    Veröffentlicht 2009
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  15. 15
    Proteasome inhibitors in multiple myeloma: 10 years later

    Proteasome inhibitors in multiple myeloma: 10 years later von Philippe Moreau, Paul G. Richardson, Michèle Cavo, Robert Z. Orlowski, Jesús F. San Miguel, Antonio Palumbo, Jean‐Luc Harousseau

    Veröffentlicht 2012
    Volltext Volltext
    Revisão
    Zu den Favoriten
    Gespeichert in:
  16. 16
    Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma

    Phase 2 dose-expansion study (PX-171-006) of carfilzomib, lenalidomide, and low-dose dexamethasone in relapsed or progressive multiple myeloma von Michael Wang, Tom Martin, William Bensinger, Melissa Alsina, David S. Siegel, Edward Kavalerchik, Mei Huang, Robert Z. Orlowski, Rubén Niesvizky

    Veröffentlicht 2013
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  17. 17
    <i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

    <i>In Vitro</i> and <i>In Vivo</i> Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells von Dharminder Chauhan, Ze Tian, Bin Zhou, Deborah J. Kuhn, Robert Z. Orlowski, Noopur Raje, Paul Richardson, Kenneth C. Anderson

    Veröffentlicht 2011
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  18. 18
    Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death

    Targeted inhibition of interleukin‐6 with CNTO 328 sensitizes pre‐clinical models of multiple myeloma to dexamethasone‐mediated cell death von Peter M. Voorhees, Qing Chen, George W. Small, Deborah J. Kuhn, Sally A. Hunsucker, Jeffrey A. Nemeth, Robert Z. Orlowski

    Veröffentlicht 2009
    Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  19. 19
    MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis

    MUC20 regulated by extrachromosomal circular DNA attenuates proteasome inhibitor resistance of multiple myeloma by modulating cuproptosis von Xiaobin Wang, Yingqing Shi, Hua Shi, Xiaoyu Liu, Liao Ai-jun, Zhuogang Liu, Robert Z. Orlowski, Rui Zhang, Huihan Wang

    Veröffentlicht 2024
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:
  20. 20
    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide therapy

    Combined pegylated liposomal doxorubicin and bortezomib is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/lenalidomide th... von Pieter Sonneveld, Roman Hájek, Arnon Nagler, Andrew Spencer, Joan Bladé, Tadeusz Robak, Sen Hong Zhuang, Jean‐Luc Harousseau, Robert Z. Orlowski

    Veröffentlicht 2008
    Volltext Volltext
    Artigo
    Zu den Favoriten
    Gespeichert in:

Suchwerkzeuge: